You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中恆集團(600252.SH):萊美藥業擬轉讓成都美康35%股權及四川美康2.25%股權
格隆匯 03-11 20:28

格隆匯3月11日丨中恆集團(600252.SH)公佈,公司控股子公司萊美藥業參與投資設立了常州萊美青楓醫藥產業投資中心(有限合夥)(以下簡稱“萊美青楓”),萊美藥業持有萊美青楓29.90%份額。四川美康醫藥軟件研究開發有限公司(以下簡稱“四川美康”)和成都美康醫藥信息系統有限公司(以下簡稱“成都美康”)為萊美青楓對外投資的企業,萊美藥業將通過萊美青楓持有的成都美康35%股權、四川美康2.25%股權分別以人民幣1.995億元和人民幣1350萬元轉讓給自然人賴琪。本次股權轉讓交易完成後,萊美藥業將不再間接持有聯營企業四川美康和成都美康股權。

四川美康主營業務為醫藥軟件技術開發,其業務不在萊美藥業未來聚焦腫瘤、消化道細分領域的戰略規劃範圍內,萊美藥業為聚焦抗腫瘤、消化道、抗感染等優勢細分領域,決定通過萊美青楓將其持有四川美康和成都美康股權對外轉讓。本次股權轉讓完成後,將有利於更好地配置公司資源、提高資產運營效率,符合公司未來發展戰略規劃。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account